We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Analyst: Ranbaxy Could Sell Rights to Generic Lipitor or Delay Launch
Analyst: Ranbaxy Could Sell Rights to Generic Lipitor or Delay Launch
August 18, 2011
Ranbaxy Laboratories could sell its 180-day exclusivity rights for a generic of Pfizer’s Lipitor if the FDA’s approval timeline for the drug remains unclear. Alternatively, Ranbaxy could delay its launch, pushing back the start of its exclusivity period, analysts say.